Astellas To Invest ¥5.5 Billion To Construct Chemical Compounds Factory For New Drug Development
This article was originally published in PharmAsia News
Executive Summary
Astellas announced April 7 plans to build a chemical compounds production facility at its Toyama factory. The company plans to invest ¥5.5 billion and start the construction in September. To be completed in 2010, the 9,000 square meter, three-story facility will manufacture multiple compounds to be used in clinical trails for new drug development. Currently, Astellas manufactures atopic drug Protopic (tacrolimus), a chemical compound developed from fermented natural products at the Toyama factory; the company plans to manufacture similar compounds at the new facility. (Click here for more - Japanese language
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.